A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

NCT07682272 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

Interventions

DRUG: SHR-8068 Injection
DRUG: Adebrelimab Injection
DRUG: Apatinib Mesylate Tablets

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.